West Pharmaceutical Services, Inc.

▲ Bull Case

• ◆GLP-1 injectable demand grows from 18% to 30%+ of revenue by FY2028, driven by already-contracted Novo Nordisk and Eli Lilly manufacturing programs locked in via DMF regulatory filings, adding ~$396M incremental revenue and ~$1.60 adj. EPS without requiring new customer wins.
• ◆HVP mix-shift accelerates from 48% to 63–68% of Proprietary Products, adding 300–500bps of gross margin through commercial conversion of existing customers to premium formats — a controllable execution task, not a technology risk — driving adj. EPS to $14–15 by FY2028.
• ◆CEO transition resolves with an internal hire ensuring strategic continuity; FCF compounds to $900M+ by FY2028; net cash builds to $1.5B+; multiple expands as market reprices WST from 'quality compounder' to 'GLP-1 infrastructure quasi-monopoly,' supporting a $520 price target (+78%).

▼ Bear Case

• ◆External CEO hire with non-pharma background creates strategic uncertainty, potentially disrupting the 11-year HVP compounding playbook and depressing the multiple to 28–30x as investors await strategic clarity.
• ◆GLP-1 revenue ramp slows to 18–20% of sales as Novo/Lilly manufacturing scale-up faces API supply constraints or production delays, eroding the primary bull case driver and causing organic growth to fall below guidance at <5% for two consecutive quarters.
• ◆HVP mix-shift stalls below 53% in FY2026 and multiple compresses to 28–30x; adj. EPS of $8.00–8.40 supports a $240 price target (−18.6% total return of −16.9%), though the bear case is protected by $588M net cash and $555M+ FCF — a price loss, not permanent capital impairment.

“Consensus views WST as a premium-multiple quality compounder trading at historical fair value (~35x), with GLP-1 as a meaningful but incremental tailwind among several growth drivers — implying limited near-term upside. The variant perception is that GLP-1 is not merely a tailwind but a franchise-transforming, multi-decade demand program locked in via regulatory filings. At 30% of a potential $5B FY2028 revenue base, GLP-1 alone would generate more revenue than WST's entire FY2019 business. If the market reprices WST from 'quality compounder' to 'GLP-1 infrastructure quasi-monopoly,' the multiple expansion would make the bull scenario the modal 5-year outcome. The key unresolved debate is timing and magnitude of GLP-1 ramp (22% vs. 30%+ of revenue by FY2028) and the strategic implications of the CEO transition.”

• ◆CEO successor announcement (H2 2026) — most important single near-term catalyst; internal hire signals strategy continuity and multiple re-rating
• ◆Q2 2026 earnings GLP-1 % of sales disclosure (August 2026) — confirmation of ramp from 18% toward 20–22%
• ◆SmartDose divestiture completion and proceeds deployment (buybacks vs. M&A signals capital allocation priority)
• ◆FY2026 adj. EPS delivery at or above $8.575 guidance midpoint (February 2027 — confirms operating leverage and HVP mix-shift)
• ◆Novo Nordisk / Eli Lilly GLP-1 manufacturing capacity announcements confirming WST NovaPure component volumes
• ◆HVP mix reaching 53%+ of Proprietary Products in FY2026 (gross margin expansion visible)

• ◆CEO transition: external hire with non-pharma background disrupts HVP compounding strategy and depresses multiple to 28–30x
• ◆GLP-1 injectable demand disruption: Phase 3 oral GLP-1 demonstrating efficacy within 15% of injectable at 12+ month follow-up could bifurcate market and delay/reduce WST's 30% revenue share thesis
• ◆GLP-1 ramp deceleration: Novo/Lilly manufacturing scale-up slower than disclosed CapEx implies; API supply constraints; GLP-1 falls below 15% of revenue for two consecutive quarters
• ◆Organic growth deceleration below 5% for two consecutive quarters indicating destocking re-emergence or end-market softening
• ◆Large acquisition (>$1B) by new CEO consuming $588M net cash for integration rather than compounding, undermining capital-light DMF thesis
• ◆HVP mix-shift stall below 53% in FY2026, delaying gross margin expansion timeline by 1–2 years
• ◆Transcript/disclosure gap: precise GLP-1 % of revenue, SmartDose divestiture terms, and CEO transition process details not available from filings alone